Department of Kidney Transplantation, Second Xiangya Hospital, Central South University, Changsha 410011.
Clinical Research Center for Organ Transplantation in Hunan Province, Changsha 410011.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Jul 28;48(7):1017-1025. doi: 10.11817/j.issn.1672-7347.2023.230079.
Immunoglobulin A nephropathy (IgAN) is one of the most common types of kidney disease, and kidney transplantation is the most effective treatment for end-stage renal disease. This study aims to analyze the clinical curative effect of renal transplantation for adults with IgAN and to discuss the efficacy and safety of kidney transplantation for IgAN at the perioperative period and medium- and long-term follow-up.
This retrospective study included the clinical and follow-up data of 81 adult patients with IgAN who underwent kidney transplantation at the Second Xiangya Hospital, Central South University from January 2018 to January 2022. Of the 81 patients whose age at (34.1±9.9) years old, 47 (58.0%) were male. The body mass index was (20.8±3.2) kg/m, and the human leukocyte antigen (HLA) mismatch number was 3.5±1.2. The estimated glomerular filtration rate (eGFR) and daily 24-hour urine output for the recipients on the 1st, 5th, and 7th day after kidney transplantation and when they were discharged were analyzed. The recovery of the transplanted kidney and occurrence of complications were comprehensively evaluated. The eGFR, urinary protein, and occult blood were evaluated at the 6th, 12th, 24th, 36th, and 48th month and at the last follow-up.
The follow-up time was (25.7±15.8) months. No primary non-function occurred in any patient during the perioperative period time. Fifty-one (63.0%) patients had immediate graft function recovery, and 16 (19.8%) patients had slow graft function recovery. Delayed recovery of graft function was observed in 14 (17.3%) patients. A total of 19 perioperative complications occurred, including 9 patients with acute rejection, 5 patients with urinary fistula, 1 thrombosis in both lower limbs, and 4 lymphatic fistula. The eGFR at 6th, 12th, 24th, 36th, and 48th month of follow-up were (65.3±22.9), (67.6±23.0), (64.3±21.8), (65.9±24.7), and (68.7±31.2) mL/(min·1.73 m), respectively. The eGFR remained high during the medium- and long-term follow-ups. At the longest follow-up of 56 months, eGFR fluctuation was still mild, and the positive rate of urine protein and occult blood was low. IgAN recurred in 4 transplanted kidneys, accounting for 4.94% of the total patients, without severe renal insufficiency. Three patients had kidney dysfunction due to severe pneumonia, rejection, and stone in the transplanted kidney. The overall survival rate of the transplanted kidney was higher than 95%, and the survival rate of all patients was 100% till Januray 2022.
Renal transplantation for adults with IgAN had a remarkable short-term effect. The recipients can be beneficial significantly to favorable midium- and long-term outcomes. IgAN recurrence is infrequent and rarely causes severe renal function damage.
免疫球蛋白 A 肾病(IgAN)是最常见的肾脏疾病之一,肾脏移植是治疗终末期肾病最有效的方法。本研究旨在分析成人 IgAN 患者肾脏移植的临床疗效,并探讨围手术期和中、长期随访期间肾脏移植治疗 IgAN 的疗效和安全性。
本回顾性研究纳入了 2018 年 1 月至 2022 年 1 月期间在中南大学湘雅二医院接受肾脏移植的 81 例成人 IgAN 患者的临床和随访数据。81 例患者的年龄为(34.1±9.9)岁,其中 47 例(58.0%)为男性。体重指数为(20.8±3.2)kg/m²,人类白细胞抗原(HLA)错配数为 3.5±1.2。分析了移植肾受者术后第 1、5、7 天和出院时的估计肾小球滤过率(eGFR)和 24 小时尿量。综合评估移植肾的恢复和并发症的发生情况。在第 6、12、24、36 和 48 个月和最后一次随访时评估了 eGFR、尿蛋白和潜血。
随访时间为(25.7±15.8)个月。围手术期无患者发生原发性无功能。51 例(63.0%)患者立即恢复移植肾功能,16 例(19.8%)患者恢复缓慢。14 例(17.3%)患者出现移植肾功能延迟恢复。共发生 19 例围手术期并发症,包括 9 例急性排斥反应,5 例尿瘘,1 例双下肢血栓形成,4 例淋巴瘘。第 6、12、24、36 和 48 个月的 eGFR 分别为(65.3±22.9)、(67.6±23.0)、(64.3±21.8)、(65.9±24.7)和(68.7±31.2)mL/(min·1.73 m)。eGFR 在中、长期随访中仍保持较高水平。在最长的 56 个月随访中,eGFR 波动仍较轻微,尿蛋白和潜血阳性率较低。4 例移植肾发生 IgAN 复发,占总患者的 4.94%,无严重肾功能不全。3 例患者因严重肺炎、排斥反应和移植肾结石导致肾功能障碍。移植肾的总体存活率高于 95%,截至 2022 年 1 月,所有患者的存活率均为 100%。
成人 IgAN 患者的肾脏移植具有显著的短期效果。受者可以从中获得显著的中、长期获益。IgAN 复发频率较低,很少导致严重的肾功能损害。